Table 2.

Relative risk of all-grade and high-grade (grade ≥ 3) hypertension of several VSP inhibitor agents, described in meta-analyses

	All grade hypertension			High grade hypertension
	RRa	95 % CI	p Value	RRa	95 % CI	p Value
Bevacizumab [33]	3.02	2.24–4.07	<0.001	5.28	4.15–6.71	0.001
Sunitinib [52]	3.44	0.62–19.15	0.16	22.72	4.48–115.29	<0.001
Axitinib [38]	3.00	1.29–6.97	0.01	1.71	1.21–2.43	0.003
Sorafenib [62]	3.07	2.05–4.60	<0.01	3.31	2.21–4.95	<0.01
Pazopanib [65]	4.97	3.38–7.30	<0.001	2.87	1.16–7.11	0.023
Lenvatinib [69]	7.44	4.31–12.85	<0.001	18.2	5.90–56.32	<0.001
Vandetanib [36]	5.10	3.76–6.92	<0.001	8.06	3.41–19.04	0.001
Regorafenib [74]	3.76	2.35–5.99	<0.001	8.39	3.10–22.71	0.001

Abbreviations: RR relative risk, CI confidence interval

^a Relative risk of new onset hypertension during trial period in interventional group compared to control